QNCX Jan 2025 2.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 2.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 19 |
Business WireQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
SOUTH SAN FRANCISCO, Calif., June 03, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T). EryDex is comprised of dexamethasone sodium phosphate (DSP)
Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 13, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024.
Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time.
